Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot2 - STU 1 ballot International flag

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot2 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

Table of Contents

Page standards status: Informative
.. 0 Table of Contents
... 1 Introduction
... 2 Evidence Profiles
... 3 EvidenceVariable Profiles
... 4 Group Profiles
... 5 Citation Profiles
... 6 ArtifactAssessment Profiles
... 7 Composition Profiles
... 8 Other Profiles
... 9 Profiles
... 10 Extensions
... 11 Terminologies
... 12 Examples
... 13 Downloads
... 14 Artifacts Summary
.... 14.1 Adaptation
.... 14.2 BaselineMeasureEvidence
.... 14.3 BaselineMeasureReport
.... 14.4 BaselineVariablesList
.... 14.5 BookCitation
.... 14.6 BookPartCitation
.... 14.7 CertaintyOfEvidence
.... 14.8 Classification
.... 14.9 CohortDefinition
.... 14.10 Comment
.... 14.11 ComparativeBaselineMeasureEvidence
.... 14.12 ComparativeEvidence
.... 14.13 ComparativeEvidenceReport
.... 14.14 ComparativeEvidenceReportExpanded
.... 14.15 ComparativeEvidenceReportSubject
.... 14.16 ComparativeEvidenceSynthesisReport
.... 14.17 ComparativeParticipantFlowEvidence
.... 14.18 ComparatorGroup
.... 14.19 ComparatorOnlyEvidence
.... 14.20 Comparison
.... 14.21 CompositeRating
.... 14.22 ConceptualCohortDefinition
.... 14.23 ConceptualComparatorDefinition
.... 14.24 ConceptualExposureDefinition
.... 14.25 DatabaseCitation
.... 14.26 DatabaseEntryCitation
.... 14.27 DatasetCitation
.... 14.28 DateAsRating
.... 14.29 DichotomousIntendedOutcome
.... 14.30 EndpointAnalysisPlan
.... 14.31 EvidenceAssessment
.... 14.32 EvidenceList
.... 14.33 EvidenceReport
.... 14.34 EvidenceReportPackage
.... 14.35 EvidenceReportSubject
.... 14.36 EvidenceSynthesisEvidence
.... 14.37 ExposureGroup
.... 14.38 GroupAssignment
.... 14.39 GroupR6
.... 14.40 Guideline
.... 14.41 GuidelineRegistryRecord
.... 14.42 InterventionOnlyEvidence
.... 14.43 JournalArticleCitation
.... 14.44 M11Report
.... 14.45 MetaanalysisEligibilityCriteria
.... 14.46 MetaanalysisOutcomeDefinition
.... 14.47 MetaanalysisStudyGroup
.... 14.48 NetEffectContribution
.... 14.49 NetEffectContributionList
.... 14.50 NetEffectContributions
.... 14.51 NetEffectEstimate
.... 14.52 NonComparativeEvidence
.... 14.53 OutcomeDefinition
.... 14.54 OutcomeImportance
.... 14.55 OutcomeList
.... 14.56 OutcomeMeasureReport
.... 14.57 OutcomeVariablesList
.... 14.58 ParticipantFlowEvidence
.... 14.59 ParticipantFlowEvidenceVariable
.... 14.60 ParticipantFlowReasonEvidenceVariable
.... 14.61 ParticipantFlowReport
.... 14.62 ParticipantFlowVariablesList
.... 14.63 PreprintCitation
.... 14.64 Rating
.... 14.65 Recommendation
.... 14.66 RecommendationAction
.... 14.67 RecommendationEligibilityCriteria
.... 14.68 RecommendationJustification
.... 14.69 RecommendationPlan
.... 14.70 RecommendationRating
.... 14.71 ResearchStudyDataDictionary
.... 14.72 ResearchStudySupport
.... 14.73 RiskOfBias
.... 14.74 SearchResults
.... 14.75 SearchStrategy
.... 14.76 SingleStudyEvidence
.... 14.77 SoaPlanDefinition
.... 14.78 SoftwareCitation
.... 14.79 StatisticModel
.... 14.80 StudyDesign
.... 14.81 StudyEligibilityCriteria
.... 14.82 StudyGroup
.... 14.83 StudyRegistryRecord
.... 14.84 SummaryOfFindings
.... 14.85 SummaryOfNetEffect
.... 14.86 SystematicReview
.... 14.87 SystematicReviewEligibilityCriteria
.... 14.88 SystematicReviewExcludedStudies
.... 14.89 SystematicReviewIncludedStudies
.... 14.90 VariableDefinition
.... 14.91 WebPageCitation
.... 14.92 AdditionalLanguage
.... 14.93 ArtifactAssessmentCompared
.... 14.94 ArtifactAssessmentDateAsRating
.... 14.95 ArtifactPublicationStatus
.... 14.96 CharacteristicTiming
.... 14.97 CiteAs
.... 14.98 CompositionExtendedContactDetail
.... 14.99 EvidenceVariableHandlingDetail
.... 14.100 GuidelineRegistration
.... 14.101 NumberAnalyzed
.... 14.102 PublicationDate
.... 14.103 RelatesTo
.... 14.104 RelatesToClassifier
.... 14.105 RelatesToWithQuotation
.... 14.106 RelativeOutcomeImportance
.... 14.107 ResearchStudyExcludedStudy
.... 14.108 ResearchStudyIncludedStudy
.... 14.109 ResearchStudyIsLowInterventionTrial
.... 14.110 ResearchStudyNumberOfStudiesIdentified
.... 14.111 ResearchStudyNumberOfStudiesIncluded
.... 14.112 ResearchStudySaeReportingMethod
.... 14.113 ResearchStudySearchStrategy
.... 14.114 ResearchStudySponsorConfidentialityStatement
.... 14.115 ResearchStudyStudyAmendment
.... 14.116 ResearchStudySystematicReviewEligibilityCriteria
.... 14.117 StatisticModelExpression
.... 14.118 StatisticModelIncludeIf
.... 14.119 EBMonFHIR Profile Name Value Set
.... 14.120 Evidence Rating System Classifier Codes Value Set
.... 14.121 Recommendation Justification Classifier Codes Value Set
.... 14.122 Research Study Document Types Value Set
.... 14.123 Search Strategy Characteristic Value Set
.... 14.124 EBMonFHIR Profile Name Code System
.... 14.125 Evidence Rating System Classifier Code System
.... 14.126 Research Study Document Types Code System
.... 14.127 Search Strategy Characteristic Code System
.... 14.128 11232013 Rosiglitazone monotherapy is effective in patients with type 2 diabetes.
.... 14.129 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)
.... 14.130 14706014 Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist.
.... 14.131 15832493 Spotlight on rosiglitazone in the management of type 2 diabetes mellitus.
.... 14.132 15855602 Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia.
.... 14.133 179899
.... 14.134 18160893 Wonder woman. Like my childhood heroine, Mrs. Betty also had amazing powers.
.... 14.135 18508207 A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal.
.... 14.136 19029421 Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer.
.... 14.137 19091394 Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.
.... 14.138 19967827 Wonder woman was Argentine and her real name was Evita.
.... 14.139 22056152 Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial.
.... 14.140 22502942 Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial.
.... 14.141 23306100 Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.
.... 14.142 23452809 Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer.
.... 14.143 23589542 Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society.
.... 14.144 23604530 A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer.
.... 14.145 24598155 Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer.
.... 14.146 25301760 Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).
.... 14.147 26002607 Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra.
.... 14.148 26028518 Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
.... 14.149 26092557 Feasibility study of a randomized controlled trial comparing docetaxel chemotherapy and androgen deprivation therapy with sequential prostatic biopsies from patients with advanced non-castration-resistant prostate cancer.
.... 14.150 26244877 Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.
.... 14.151 26502880 A novel nasal powder formulation of glucagon: toxicology studies in animal models.
.... 14.152 26681725 Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study.
.... 14.153 26859072 Emotional Distress in the Partners of Type 1 Diabetes Adults: Worries About Hypoglycemia and Other Key Concerns.
.... 14.154 27222544 Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations.
.... 14.155 27308831 Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis.
.... 14.156 27979893 6. Glycemic Targets.
.... 14.157 29114761 Web Exclusives. Annals Story Slam - How Wonder Woman Became My Alter Ego.
.... 14.158 29114762 Web Exclusives. Annals Story Slam - Wonder Woman Is a Cartoon Character.
.... 14.159 29202628 "I Kinda Feel Like Wonder Woman": An Interpretative Phenomenological Analysis of Pole Fitness and Positive Body Image.
.... 14.160 29357271 Using Hawkeye from the Avengers to communicate on the eye.
.... 14.161 29694275 A regressive formula of perversity: Wertham and the women of comics.
.... 14.162 29694302 Introduction: "Suffering Sappho!": Lesbian content and queer female characters in comics.
.... 14.163 30467172 Finding my inner Wonder Woman.
.... 14.164 30545967 Parachute use to prevent death and major trauma when jumping from aircraft: randomized controlled trial.
.... 14.165 34871555 What Can Wonder Woman Teach Radiologists?
.... 14.166 35243488 Bariatric surgery and cardiovascular disease: a systematic review and meta-analysis.
.... 14.167 36491989 Another Georgia Wonder Woman: She Does More Astounding Tricks Than Did Lula Hurst.
.... 14.168 367832
.... 14.169 367833
.... 14.170 37024129 Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.
.... 14.171 38584159 Efficacy and safety of a four-drug, quarter-dose treatment for hypertension: the QUARTET USA randomized trial.
.... 14.172 6907780 Career guide: to change what needs changing...doesn't take Wonder Woman.
.... 14.173 A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 14.174 ADAS-Cog(11) EndpointAnalysisPlan from PHUSE Lilly Redacted Protocol - EBMonFHIR IG Version
.... 14.175 Add-on Amlodipine at 6 weeks
.... 14.176 Adults with diabetes mellitus type 2
.... 14.177 Adults with diabetes type 2 and established CVD (but no CKD)
.... 14.178 Adults with type 2 diabetes, CVD and CKD
.... 14.179 Adverse event free and hypertension control
.... 14.180 Adverse event free and hypertension control at 12 weeks
.... 14.181 Adverse Events Report for NCT03640312
.... 14.182 Age
.... 14.183 Age with comparator
.... 14.184 Age with intervention
.... 14.185 Aircraft Type
.... 14.186 Aircraft Type with comparator
.... 14.187 Aircraft Type with intervention
.... 14.188 Altitude
.... 14.189 Altitude comparing intervention vs. comparator
.... 14.190 Altitude for enrolled group
.... 14.191 Altitude for screened group
.... 14.192 Altitude with comparator
.... 14.193 Altitude with intervention
.... 14.194 Analyzed Group in PARACHUTE Trial
.... 14.195 Anticoagulation for COVID-19 Combined RCTs in NEJM
.... 14.196 Baseline Characteristics Report for NCT03640312
.... 14.197 Baseline Measure Report: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 14.198 Baseline Measures List for PARACHUTE Trial
.... 14.199 BaselineMeasureEvidence: Age in 2018 Norwegian Cohort Medical Group
.... 14.200 BaselineMeasureEvidence: Age in 2018 Norwegian Cohort Surgical Group
.... 14.201 BaselineMeasureEvidence: BMI in 2018 Norwegian Cohort Medical Group
.... 14.202 BaselineMeasureEvidence: BMI in 2018 Norwegian Cohort Surgical Group
.... 14.203 BaselineVariablesList: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 14.204 Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials
.... 14.205 BookCitation: Crossing the Quality Chasm: A New Health System for the 21st Century
.... 14.206 BookPartCitation: Chapter 3 of Crossing the Quality Chasm: A New Health System for the 21st Century
.... 14.207 BookPartCitation: Chapter 3 of Crossing the Quality Chasm: A New Health System for the 21st Century - without baseCitation
.... 14.208 Candesartan 8 mg once daily
.... 14.209 Certainty of Evidence Rating of 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)
.... 14.210 Change in Mean Diastolic Blood Pressure (NCT03640312)
.... 14.211 Change in Mean Diastolic Blood Pressure at 6 weeks for Candesartan in NCT03640312
.... 14.212 Change in Mean Diastolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312
.... 14.213 Change in Mean Diastolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.214 Change in Mean Systolic Blood Pressure (NCT03640312)
.... 14.215 Change in Mean Systolic Blood Pressure (NCT03640312)
.... 14.216 Change in Mean Systolic Blood Pressure at 12 weeks for Candesartan in NCT03640312
.... 14.217 Change in Mean Systolic Blood Pressure at 12 weeks for QUARTET LDQT in NCT03640312
.... 14.218 Change in Mean Systolic Blood Pressure at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.219 Change in Mean Systolic Blood Pressure at 6 weeks for Candesartan in NCT03640312
.... 14.220 Change in Mean Systolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312
.... 14.221 Change in Mean Systolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.222 CIBIC+ EndpointAnalysisPlan from PHUSE Lilly Redacted Protocol - EBMonFHIR IG Version
.... 14.223 Citation for Composition: ComparativeEvidenceReport: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 14.224 Citation for EBMonFHIR Implementation Guide
.... 14.225 Citation for FEvIR Evidence 55: 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)
.... 14.226 Citation for FEvIR Evidence 7637: Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill COVID-19
.... 14.227 Classification: Study Design for Association of Bariatric Surgery with Complications and Comorbidities JAMA 2018 Norwegian Cohort
.... 14.228 Comment on Guideline: ADA 2021 Standards of Medical Care 8. Obesity Management for the Treatment of Type 2 Diabetes by Joanne Dehnbostel 2023-11-28T15:19:01.266Z
.... 14.229 Comparative Evidence Report for QUARTET USA Trial
.... 14.230 ComparativeBaselineMeasureEvidence: Age in 2018 Norwegian Cohort Surgical Group vs. Medical Group
.... 14.231 ComparativeBaselineMeasureEvidence: BMI in 2018 Norwegian Cohort Surgical Group vs. Medical Group
.... 14.232 ComparativeEvidence: All-cause mortality effect of bariatric surgery in 2022 meta-analysis
.... 14.233 ComparativeEvidence: Bariatric Surgery effect for ADA triple outcome at 5 years (Diabetes Surgery Study)
.... 14.234 ComparativeEvidence: Bypass surgery effects on Additional GI surgical procedure in JAMA 2018 Norwegian cohort study
.... 14.235 ComparativeEvidence: Bypass surgery effects on Myocardial infarction or stroke in Swedish Obese Subjects (SOS) study
.... 14.236 ComparativeEvidence: Bypass surgery effects on New onset depression in JAMA 2018 Norwegian cohort study
.... 14.237 ComparativeEvidence: Bypass surgery effects on Remission of diabetes in JAMA 2018 Norwegian cohort study
.... 14.238 ComparativeEvidence: Bypass surgery effects on Treatment with opioids in JAMA 2018 Norwegian cohort study
.... 14.239 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Courcoulas 2014
.... 14.240 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Courcoulas 2015
.... 14.241 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Cummings 2016
.... 14.242 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Ding 2015
.... 14.243 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Dixon 2008
.... 14.244 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Halperin 2014
.... 14.245 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Ikramuddin 2013
.... 14.246 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Ikramuddin 2015
.... 14.247 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Liang 2013
.... 14.248 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Mingrone 2012 (DIBASY) trial
.... 14.249 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Mingrone 2015 (DIBASY) trial
.... 14.250 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Parikh 2014
.... 14.251 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Schauer 2012 (STAMPEDE) trial
.... 14.252 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Schauer 2014 (STAMPEDE) trial
.... 14.253 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Wentworth 2014
.... 14.254 ComparativeEvidence: Mean difference in HbA1c effect of bariatric surgery in 2016 meta-analysis
.... 14.255 ComparativeEvidenceReport: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 14.256 ComparativeEvidenceReportSubject: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 14.257 ComparativeEvidenceSynthesisReport: GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.258 ComparativeParticipantFlowEvidence: Dropout due to stopping intervention Lofexidine vs. Placebo in opioid detoxification trial
.... 14.259 ComparatorDefinition: Glucagon-Like Peptide-1 (GLP-1) receptor agonists
.... 14.260 ComparatorDefinition: Obese patients ≥ 18 years old without bariatric surgery
.... 14.261 ComparatorDefinition: Standard care
.... 14.262 ComparatorGroup: JAMA 2018 Norwegian cohort study Control cohort
.... 14.263 ComparatorOnlyEvidence: Additional GI surgical procedure without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study
.... 14.264 ComparatorOnlyEvidence: All-cause mortality without bariatric surgery in 2022 meta-analysis
.... 14.265 ComparatorOnlyEvidence: Myocardial infarction or stroke without bariatric surgery (Control Group) in Swedish Obese Subjects (SOS) study
.... 14.266 ComparatorOnlyEvidence: New onset depression without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study
.... 14.267 ComparatorOnlyEvidence: Remission of diabetes without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study
.... 14.268 ComparatorOnlyEvidence: Treatment with opioids without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study
.... 14.269 Comparison: Original and Adapted Recommendation: ADA Obesity Management Recommendation 8.16
.... 14.270 Composite Rating of FOI 153881 for Project FOI 112280
.... 14.271 Computable_Publishing_LLC
.... 14.272 ConceptualCohortDefinition: At least 2 risk factors for stroke
.... 14.273 ConceptualCohortDefinition: BMI 27.5-32.4 in Asian Americans who do not achieve durable weight loss and improvement in comorbidities without surgery
.... 14.274 ConceptualCohortDefinition: BMI 30-34.9 in persons who do not achieve durable weight loss and improvement in comorbidities without surgery
.... 14.275 ConceptualCohortDefinition: BMI 32.5-37.4 in Asian Americans who do not achieve durable weight loss and improvement in comorbidities without surgery
.... 14.276 ConceptualCohortDefinition: BMI 35-39.9 in persons who do not achieve durable weight loss and improvement in comorbidities without surgery
.... 14.277 ConceptualCohortDefinition: BMI criteria for ADA surgery recommendation
.... 14.278 ConceptualCohortDefinition: BMI ≥ 35 and at least 1 obesity-related comorbidity
.... 14.279 ConceptualCohortDefinition: BMI ≥ 37.5 kg/m2 in Asian Americans
.... 14.280 ConceptualCohortDefinition: Estimated glomerular filtration rate 45-59
.... 14.281 ConceptualCohortDefinition: Heart failure based on Phenotypes
.... 14.282 ConceptualCohortDefinition: Lower BMI criteria for ADA surgery consideration
.... 14.283 ConceptualCohortDefinition: Meet either T1DM-specific eligibility criteria or T2DM-specific eligibility criteria
.... 14.284 ConceptualCohortDefinition: Nonfatal myocardial infarction
.... 14.285 ConceptualCohortDefinition: Nonfatal stroke
.... 14.286 ConceptualCohortDefinition: Oxygen saturation < 96% on Boots Finger Pulse Oximeter
.... 14.287 ConceptualCohortDefinition: Oxygen saturation < 96% on Boots Finger Pulse Oximeter with Ranges
.... 14.288 ConceptualCohortDefinition: Proxy criteria for surgical candidates
.... 14.289 ConceptualCohortDefinition: Severe obesity
.... 14.290 ConceptualCohortDefinition: T1DM or T2DM
.... 14.291 ConceptualCohortDefinition: T1DM-specific criteria
.... 14.292 ConceptualCohortDefinition: T2DM-specific criteria
.... 14.293 ConceptualCohortDefinition_Cancer_of_any_kind_except_basal_cell_skin_cancer_or_cancer_in_situ_unless_documented_to_be_disease_free_for_five_years
.... 14.294 ConceptualCohortDefinition_Cardiovascular_event
.... 14.295 ConceptualComparatorDefinition: NOT Bariatric Surgery (RYGB, VSG, LAGB, BPD)
.... 14.296 ConceptualComparatorDefinition: Usual-care pharmacologic thromboprophylaxis
.... 14.297 ConceptualExposureDefinition: Bariatric Surgery (RYGB, VSG, LAGB, BPD)
.... 14.298 ConceptualExposureDefinition: Therapeutic-dose anticoagulation with heparin
.... 14.299 COVID_19PneumoniaHospitalizedAdult
.... 14.300 Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill patients with COVID-19
.... 14.301 CTIS2024-516402-32-00 Eligibility Criteria
.... 14.302 CTIS2024-516402-32-00 Primary Outcome 1
.... 14.303 CTIS2024-516402-32-00 Secondary Outcome 1
.... 14.304 CTIS2024-516402-32-00 Secondary Outcome 2
.... 14.305 CTIS2024-516402-32-00 Secondary Outcome 3
.... 14.306 CTIS2024-516402-32-00 Secondary Outcome 4
.... 14.307 CTIS2024-516402-32-00 Secondary Outcome 5
.... 14.308 CTIS2024-516402-32-00 Secondary Outcome 6
.... 14.309 CTIS2024-516402-32-00 Secondary Outcome 7
.... 14.310 CTIS2024-516402-32-00 Secondary Outcome 8
.... 14.311 DatabaseCitation: Citation for FEvIR Platform
.... 14.312 DatabaseEntryCitation: ComparativeEvidenceReport: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 14.313 DatasetCitation: Extrachromosomal DNA Amplification Contributes to Small Cell Lung Cancer Heterogeneity and is Associated with Worse Outcomes
.... 14.314 DateOfFirstPublication Classification of FOI 153881 by Rachel Couban
.... 14.315 Death or Major Traumatic Injury 30 days after Impact comparing intervention vs. comparator
.... 14.316 Death or Major Traumatic Injury 30 days after Impact with comparator
.... 14.317 Death or Major Traumatic Injury 30 days after Impact with intervention
.... 14.318 Death or Major Traumatic Injury on Impact comparing intervention vs. comparator
.... 14.319 declined randomization in PARACHUTE Study
.... 14.320 deemed unsuitable by investigator in PARACHUTE Trial
.... 14.321 Delany-Moretlwe 2022 clinical trial
.... 14.322 Diabetes treatment medication
.... 14.323 Diastolic blood pressure at 12 weeks
.... 14.324 DichotomousIntendedOutcome: Death or Major Traumatic Injury within 30 days
.... 14.325 Eculizumab in hypertensive emergency-associated hemolytic uremic syndrome: a randomized multicenter controlled trial (HYPERSHU)
.... 14.326 Efficacy and Safety of a Quadruple Ultra-low-dose Treatment for Hypertension
.... 14.327 Eligibility criteria for NMA_Diabetes
.... 14.328 Eligibility Criteria for QUARTET USA Trial
.... 14.329 Enrolled Group for QUARTET USA Trial
.... 14.330 Enrolled Group PARACHUTE Trial
.... 14.331 Ethnic Group
.... 14.332 Ethnic Group with comparator
.... 14.333 Ethnic Group with intervention
.... 14.334 Evidence Based Medicine on FHIR Implementation Guide Code System
.... 14.335 Evidence for Results for Add-on Amlodipine at 6 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 14.336 Evidence for Results for Add-on Amlodipine at 6 weeks in QUARTET USA Trial Control Group
.... 14.337 Evidence for Results for Add-on Amlodipine at 6 weeks in QUARTET USA Trial Quadpill group
.... 14.338 Evidence for Results for Adverse event free and hypertension control at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 14.339 Evidence for Results for Adverse event free and hypertension control at 12 weeks in QUARTET USA Trial Control Group
.... 14.340 Evidence for Results for Adverse event free and hypertension control at 12 weeks in QUARTET USA Trial Quadpill group
.... 14.341 Evidence for Results for Diastolic blood pressure at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 14.342 Evidence for Results for Diastolic blood pressure at 12 weeks in QUARTET USA Trial Control Group
.... 14.343 Evidence for Results for Diastolic blood pressure at 12 weeks in QUARTET USA Trial Quadpill group
.... 14.344 Evidence for Results for Hypertension Control at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 14.345 Evidence for Results for Hypertension Control at 12 weeks in QUARTET USA Trial Control Group
.... 14.346 Evidence for Results for Hypertension Control at 12 weeks in QUARTET USA Trial Quadpill group
.... 14.347 Evidence for Results for Medication Adherence at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 14.348 Evidence for Results for Medication Adherence at 12 weeks in QUARTET USA Trial Control Group
.... 14.349 Evidence for Results for Medication Adherence at 12 weeks in QUARTET USA Trial Quadpill group
.... 14.350 Evidence for Results for Systolic blood pressure at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 14.351 Evidence for Results for Systolic blood pressure at 12 weeks in QUARTET USA Trial Control Group
.... 14.352 Evidence for Results for Systolic blood pressure at 12 weeks in QUARTET USA Trial Quadpill group
.... 14.353 Evidence List: Effect estimates for meta-analysis (Biegel 2020, Wang 2020, SOLIDARITY)
.... 14.354 EvidenceList: Study results included in Mean difference in HbA1c effect of bariatric surgery in 2016 meta-analysis
.... 14.355 EvidenceReportSectionCode Value Set
.... 14.356 EvidenceReportSubject: Clinical Outcomes for Effects of Bariatric Surgery
.... 14.357 EvidenceVariable Handling Extension Value Set
.... 14.358 EvidenceVariable: case_id
.... 14.359 EvidenceVariable: Patient id
.... 14.360 EvidenceVariable: Time of measurement
.... 14.361 Example EndpointAnalysisPlan from PHUSE Lilly Redacted Protocol - EBMonFHIR IG Version
.... 14.362 Excluded from PARACHUTE Study
.... 14.363 ExposureGroup: JAMA 2018 Norwegian cohort study Surgery cohort
.... 14.364 ExposureVariable: Age (as continuous variable)
.... 14.365 ExposureVariable: Body Mass Index (as continuous variable)
.... 14.366 ExposureVariable: pht013093.v1.p1 Age at diagnosis
.... 14.367 ExposureVariable: pht013093.v1.p1 RACE
.... 14.368 ExposureVariable: pht013093.v1.p1 SEX
.... 14.369 ExposureVariable: pht013093.v1.p1 SUBJECT_ID
.... 14.370 ExposureVariable: pht013094.v1.p1 ANALYTE_TYPE
.... 14.371 ExposureVariable: pht013094.v1.p1 BODY_SITE
.... 14.372 ExposureVariable: pht013094.v1.p1 IS_TUMOR
.... 14.373 ExposureVariable: pht013094.v1.p1 SAMPLE_ID
.... 14.374 ExposureVariable: pht013094.v1.p1 SAMPLE_USE
.... 14.375 ExposureVariable: pht013094.v1.p1 Source_Type
.... 14.376 Family History of Parachute Use
.... 14.377 Family History of Parachute Use with comparator
.... 14.378 Family History of Parachute Use with intervention
.... 14.379 Frequent Flier
.... 14.380 Frequent Flier with comparator
.... 14.381 Frequent Flier with intervention
.... 14.382 GLP-1 RA Group in Adults with diabetes type 2 with moderate CV risk
.... 14.383 GLP-1 RA Group in Adults with type 2 diabetes
.... 14.384 Glucagon Hydrochloride Solution (Active Comparator)
.... 14.385 Glucagon Nasal Powder (Experimental)
.... 14.386 Group Randomized to Comparator (empty backpack) in PARACHUTE Trial
.... 14.387 Group Randomized to Intervention Group (parachute) in PARACHUTE Trial
.... 14.388 GroupAssignment: Bariatric Surgery vs. no bariatric surgery
.... 14.389 GroupAssignment: ExposureDefinition: Bariatric Surgery (RYGB, VSG, LAGB, BPD) vs. ComparatorDefinition: NOT Bariatric Surgery (RYGB, VSG, LAGB, BPD)
.... 14.390 GroupAssignment: ExposureGroup: JAMA 2018 Norwegian cohort study Surgery cohort vs. ComparatorGroup: JAMA 2018 Norwegian cohort study Control cohort
.... 14.391 GroupAssignment: GLP-1 RA vs. Standard care
.... 14.392 GroupAssignment: high dose xanomeline vs. low dose xanomeline vs. placebo
.... 14.393 GroupAssignment: Jumping from aircraft with parachute vs. Jumping from aircraft with empty backpack
.... 14.394 GroupAssignment: Non Participants vs. Enrolled Participants
.... 14.395 GroupAssignment: Quadpill vs. Candesartan
.... 14.396 GroupAssignment: Roux-en-Y gastric bypass or Biliopancreatic Diversion vs. medical treatment
.... 14.397 GroupAssignment: Roux-en-Y gastric bypass surgery vs. Lifestyle-intensive medical management intervention alone
.... 14.398 GroupAssignment: Roux-en-Y gastric bypass vs. medical treatment
.... 14.399 GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA
.... 14.400 GroupAssignment: Therapeutic-dose anticoagulation with heparin vs. Usual-care pharmacologic thromboprophylaxis
.... 14.401 Guideline: ADA 2021 Standards of Medical Care 8. Obesity Management for the Treatment of Type 2 Diabetes
.... 14.402 Health Survey Score Total
.... 14.403 Health Survey Score Total comparing intervention vs. comparator
.... 14.404 Health Survey Score Total with comparator
.... 14.405 Health Survey Score Total with intervention
.... 14.406 Health Survey Score-Mental Health Subscore
.... 14.407 Health Survey Score-Mental Health Subscore comparing intervention vs. comparator
.... 14.408 Health Survey Score-Mental Health Subscore with comparator
.... 14.409 Health Survey Score-Mental Health Subscore with intervention
.... 14.410 Health Survey Score-Physical Health Subscore
.... 14.411 Health Survey Score-Physical Health Subscore comparing intervention vs. comparator
.... 14.412 Health Survey Score-Physical Health Subscore with comparator
.... 14.413 Health Survey Score-Physical Health Subscore with intervention
.... 14.414 Health-related Quality of Life (NCT03640312)
.... 14.415 Health-related Quality of Life at 12 weeks - Change in Mental Health T score (PROMIS) at (NCT03640312)
.... 14.416 Health-related Quality of Life at 12 weeks - Change in Mental Health T score (PROMIS) for Candesartan in NCT03640312
.... 14.417 Health-related Quality of Life at 12 weeks - Change in Mental Health T score (PROMIS) for QUARTET LDQT in NCT03640312
.... 14.418 Health-related Quality of Life at 12 weeks - Change in Physical Health T score (PROMIS) at (NCT03640312)
.... 14.419 Health-related Quality of Life at 12 weeks - Change in Physical Health T score (PROMIS) for Candesartan in NCT03640312
.... 14.420 Health-related Quality of Life at 12 weeks - Change in Physical Health T score (PROMIS) for QUARTET LDQT in NCT03640312
.... 14.421 Health-related Quality of Life at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.422 Health-related Quality of Life at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.423 Height
.... 14.424 Height with comparator
.... 14.425 Height with intervention
.... 14.426 High Blood Pressure Medication Value Set
.... 14.427 History of Acrophobia
.... 14.428 History of Acrophobia with comparator
.... 14.429 History of Acrophobia with intervention
.... 14.430 History of Broken Bones
.... 14.431 History of Broken Bones with comparator
.... 14.432 History of Broken Bones with intervention
.... 14.433 History of Parachute Use
.... 14.434 History of Parachute Use with comparator
.... 14.435 History of Parachute Use with intervention
.... 14.436 Hypertension Control at 12 weeks
.... 14.437 ICD-10-GM Terminale Codes
.... 14.438 Injury Severity Score 30 days after Impact comparing intervention vs. comparator
.... 14.439 Injury Severity Score 30 days after Impact with comparator
.... 14.440 Injury Severity Score 30 days after Impact with intervention
.... 14.441 Injury Severity Score on Impact comparing intervention vs. comparator
.... 14.442 Injury Severity Score on Impact with comparator
.... 14.443 Injury Severity Score on Impact with intervention
.... 14.444 International vs Domestic Flight
.... 14.445 International vs Domestic Flight with comparator
.... 14.446 International vs Domestic Flight with intervention
.... 14.447 InterventionDefinition: Glucagon-Like Peptide-1 (GLP-1) receptor agonists
.... 14.448 InterventionDefinition: Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors
.... 14.449 InterventionOnlyEvidence: Additional GI surgical procedure with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study
.... 14.450 InterventionOnlyEvidence: New onset depression with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study
.... 14.451 InterventionOnlyEvidence: Remission of diabetes with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study
.... 14.452 InterventionOnlyEvidence: Treatment with opioids with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study
.... 14.453 Investigator
.... 14.454 Investigator-by-treatment interaction for ADAS-Cog(11) ANCOVA
.... 14.455 IV remdesivir 200 mg then 100 mg/day for 9 days
.... 14.456 Joanne Dehnbostel's Adaptation Report of Recommendation: ADA Obesity Management Recommendation 8.16
.... 14.457 JournalArticleCitation: ADA 2021 Standards of Medical Care 8. Obesity Management for the Treatment of Type 2 Diabetes
.... 14.458 JournalArticleCitation: Association of Bariatric Surgery with Complications and Comorbidities JAMA 2018 Norwegian Cohort
.... 14.459 Jumping from aircraft with empty backpack
.... 14.460 Jumping from aircraft with parachute
.... 14.461 Justification for Recommendation: ADA Obesity Management Recommendation 8.16
.... 14.462 Justification for Recommendation: ADA Obesity Management Recommendation 8.17
.... 14.463 M11 IGBJ Protocol Example Eligibility Criteria
.... 14.464 M11 IGBJ Protocol Example for EBMonFHIR IG
.... 14.465 M11 Report Template Instructions
.... 14.466 MAGIC-derived ComparatorOnlyEvidence: All-cause mortality in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.467 MAGIC-derived ComparatorOnlyEvidence: All-cause mortality in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 14.468 MAGIC-derived ComparatorOnlyEvidence: Body weight in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.469 MAGIC-derived ComparatorOnlyEvidence: Body weight in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 14.470 MAGIC-derived ComparatorOnlyEvidence: Cardiovascular mortality in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.471 MAGIC-derived ComparatorOnlyEvidence: Cardiovascular mortality in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 14.472 MAGIC-derived ComparatorOnlyEvidence: Diabetic ketoacidosis in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.473 MAGIC-derived ComparatorOnlyEvidence: End-stage kidney disease in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.474 MAGIC-derived ComparatorOnlyEvidence: End-stage kidney disease in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 14.475 MAGIC-derived ComparatorOnlyEvidence: Genital infection in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.476 MAGIC-derived ComparatorOnlyEvidence: Health-related quality of life in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.477 MAGIC-derived ComparatorOnlyEvidence: Health-related quality of life in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 14.478 MAGIC-derived ComparatorOnlyEvidence: Heart failure in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.479 MAGIC-derived ComparatorOnlyEvidence: Heart failure in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 14.480 MAGIC-derived ComparatorOnlyEvidence: Nonfatal myocardial infarction in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.481 MAGIC-derived ComparatorOnlyEvidence: Nonfatal myocardial infarction in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 14.482 MAGIC-derived ComparatorOnlyEvidence: Nonfatal stroke in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.483 MAGIC-derived ComparatorOnlyEvidence: Nonfatal stroke in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 14.484 MAGIC-derived ComparatorOnlyEvidence: Serious hyperglycaemia in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.485 MAGIC-derived ComparatorOnlyEvidence: Serious hyperglycaemia in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 14.486 MAGIC-derived ComparatorOnlyEvidence: Severe gastrointestinal events in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.487 MAGIC-derived ComparatorOnlyEvidence: Severe gastrointestinal events in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 14.488 MAGIC-derived Evidence: All-cause mortality with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.489 MAGIC-derived Evidence: All-cause mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.490 MAGIC-derived Evidence: Body weight with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.491 MAGIC-derived Evidence: Body weight with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.492 MAGIC-derived Evidence: Cardiovascular mortality with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.493 MAGIC-derived Evidence: Cardiovascular mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.494 MAGIC-derived Evidence: Diabetic ketoacidosis with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.495 MAGIC-derived Evidence: End-stage kidney disease with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.496 MAGIC-derived Evidence: End-stage kidney disease with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.497 MAGIC-derived Evidence: Genital infection with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.498 MAGIC-derived Evidence: Health-related quality of life with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.499 MAGIC-derived Evidence: Health-related quality of life with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.500 MAGIC-derived Evidence: Heart failure with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.501 MAGIC-derived Evidence: Heart failure with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.502 MAGIC-derived Evidence: Nonfatal myocardial infarction with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.503 MAGIC-derived Evidence: Nonfatal myocardial infarction with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.504 MAGIC-derived Evidence: Nonfatal stroke with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.505 MAGIC-derived Evidence: Nonfatal stroke with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.506 MAGIC-derived Evidence: Serious hyperglycaemia with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.507 MAGIC-derived Evidence: Serious hyperglycaemia with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.508 MAGIC-derived Evidence: Severe gastrointestinal events with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.509 MAGIC-derived Evidence: Severe gastrointestinal events with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.510 MAGIC-derived InterventionOnlyEvidence: All-cause mortality in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 14.511 MAGIC-derived InterventionOnlyEvidence: All-cause mortality in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.512 MAGIC-derived InterventionOnlyEvidence: Body weight in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 14.513 MAGIC-derived InterventionOnlyEvidence: Body weight in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.514 MAGIC-derived InterventionOnlyEvidence: Cardiovascular mortality in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 14.515 MAGIC-derived InterventionOnlyEvidence: Cardiovascular mortality in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.516 MAGIC-derived InterventionOnlyEvidence: Diabetic ketoacidosis in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.517 MAGIC-derived InterventionOnlyEvidence: End-stage kidney disease in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 14.518 MAGIC-derived InterventionOnlyEvidence: End-stage kidney disease in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.519 MAGIC-derived InterventionOnlyEvidence: Genital infection in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.520 MAGIC-derived InterventionOnlyEvidence: Health-related quality of life in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 14.521 MAGIC-derived InterventionOnlyEvidence: Health-related quality of life in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.522 MAGIC-derived InterventionOnlyEvidence: Heart failure in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 14.523 MAGIC-derived InterventionOnlyEvidence: Heart failure in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.524 MAGIC-derived InterventionOnlyEvidence: Nonfatal myocardial infarction in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 14.525 MAGIC-derived InterventionOnlyEvidence: Nonfatal myocardial infarction in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.526 MAGIC-derived InterventionOnlyEvidence: Nonfatal stroke in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 14.527 MAGIC-derived InterventionOnlyEvidence: Nonfatal stroke in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.528 MAGIC-derived InterventionOnlyEvidence: Serious hyperglycaemia in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 14.529 MAGIC-derived InterventionOnlyEvidence: Serious hyperglycaemia in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.530 MAGIC-derived InterventionOnlyEvidence: Severe gastrointestinal events in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 14.531 MAGIC-derived InterventionOnlyEvidence: Severe gastrointestinal events in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.532 Mean Change in Blood Urea Nitrogen (NCT03640312)
.... 14.533 Mean Change in Blood Urea Nitrogen at 12 weeks for Candesartan in NCT03640312
.... 14.534 Mean Change in Blood Urea Nitrogen at 12 weeks for QUARTET LDQT in NCT03640312
.... 14.535 Mean Change in Blood Urea Nitrogen at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.536 Mean Change in Serum Creatinine (NCT03640312)
.... 14.537 Mean Change in Serum Creatinine at 12 weeks for Candesartan in NCT03640312
.... 14.538 Mean Change in Serum Creatinine at 12 weeks for QUARTET LDQT in NCT03640312
.... 14.539 Mean Change in Serum Creatinine at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.540 Mean Change in Serum Potassium (NCT03640312)
.... 14.541 Mean Change in Serum Potassium at 12 weeks for Candesartan in NCT03640312
.... 14.542 Mean Change in Serum Potassium at 12 weeks for QUARTET LDQT in NCT03640312
.... 14.543 Mean Change in Serum Potassium at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.544 Mean Change in Serum Sodium (NCT03640312)
.... 14.545 Mean Change in Serum Sodium at 12 weeks for Candesartan in NCT03640312
.... 14.546 Mean Change in Serum Sodium at 12 weeks for QUARTET LDQT in NCT03640312
.... 14.547 Mean Change in Serum Sodium at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.548 Mean Diastolic Blood Pressure (NCT03640312)
.... 14.549 Mean Diastolic Blood Pressure at 6 weeks for Candesartan in NCT03640312
.... 14.550 Mean Diastolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312
.... 14.551 Mean Diastolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.552 Mean Systolic Blood Pressure (NCT03640312)
.... 14.553 Mean Systolic Blood Pressure at 6 weeks for Candesartan in NCT03640312
.... 14.554 Mean Systolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312
.... 14.555 Mean Systolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.556 Median Age of Parachute Intervention Group
.... 14.557 Medication Adherence (NCT03640312)
.... 14.558 Medication Adherence at 12 weeks
.... 14.559 Medication Adherence at 12 weeks for Candesartan in NCT03640312
.... 14.560 Medication Adherence at 12 weeks for QUARTET LDQT in NCT03640312
.... 14.561 Medication Adherence at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.562 MetaanalysisEligibilityCriteria: Mean difference in HbA1c effect of bariatric surgery in type 2 diabetes and elevated BMI in 2016 meta-analysis
.... 14.563 MetaanalysisOutcomeDefinition: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups at end of follow-up
.... 14.564 MetaanalysisStudyGroup: Effect Estimates for Mortality at 14 days from COVID19 Remdesivir vs. Placebo RCTs
.... 14.565 MetaanalysisStudyGroup: Study results included in Mean difference in HbA1c effect of bariatric surgery in 2016 meta-analysis
.... 14.566 Mortality at 14 days
.... 14.567 NCT03640312 Eligibility Criteria
.... 14.568 NetEffectContribution: Additional GI surgical procedure for Example for GIN 2022
.... 14.569 NetEffectContribution: All-cause mortality for Example for GIN 2022
.... 14.570 NetEffectContribution: New onset depression for Example for GIN 2022
.... 14.571 NetEffectContribution: Nonfatal myocardial infarction or stroke for Example for GIN 2022
.... 14.572 NetEffectContribution: Remission of diabetes for Example for GIN 2022
.... 14.573 NetEffectContribution: Treatment with opioids for Example for GIN 2022
.... 14.574 NetEffectContributionList: Bariatric Surgery Example for GIN 2022
.... 14.575 NetEffectContributions: Bariatric Surgery Example for GIN 2022
.... 14.576 NetEffectEstimate: Bariatric Surgery Example for GIN 2022
.... 14.577 NHANES LBDGLUSI Variable Definition Cohort Definition
.... 14.578 NHANES LBDGLUSI: Fasting Glucose (mmol/L)
.... 14.579 NHANES LBXGLU Variable Definition Cohort Definition
.... 14.580 NHANES LBXGLU: Fasting Glucose (mg/dL)
.... 14.581 NHANES Plasma Fasting Glucose (GLU_J) Data Dictionary
.... 14.582 NHANES SEQN Respondent Sequence Number
.... 14.583 NHANES WTSAF2YR Variable Definition Cohort Definition
.... 14.584 NHANES WTSAF2YR: Fasting Subsample 2 Year MEC Weight
.... 14.585 Norwegian Cohort Study Comparing Bariatric Surgery vs Medical Obesity Treatment for Long-term Medical Complications and Obesity-Related Comorbidities
.... 14.586 NT-proBNP Study Data Dictionary
.... 14.587 Number of Patients Requiring Step up Treatment (NCT03640312)
.... 14.588 Number of Patients Requiring Step up Treatment at 6 weeks for Candesartan in NCT03640312
.... 14.589 Number of Patients Requiring Step up Treatment at 6 weeks for QUARTET LDQT in NCT03640312
.... 14.590 Number of Patients Requiring Step up Treatment at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.591 Organ support-free days
.... 14.592 Outcome Definition: All-cause mortality
.... 14.593 Outcome Definition: Body weight
.... 14.594 Outcome Definition: Cardiovascular mortality
.... 14.595 Outcome Definition: End-stage kidney disease
.... 14.596 Outcome Definition: Health-related quality of life
.... 14.597 Outcome Definition: Heart failure
.... 14.598 Outcome Definition: Nonfatal myocardial infarction
.... 14.599 Outcome Definition: Nonfatal stroke
.... 14.600 Outcome Definition: Serious hyperglycaemia
.... 14.601 Outcome Definition: Severe gastrointestinal events
.... 14.602 Outcome Importance Rating 100 of All-cause mortality
.... 14.603 Outcome Importance Rating 30 of Nonfatal myocardial infarction or stroke
.... 14.604 Outcome Importance Rating 5 of New onset depression
.... 14.605 Outcome Importance Rating 5 of Remission of diabetes
.... 14.606 Outcome Importance Rating 5 of Treatment with opioids
.... 14.607 Outcome Importance Rating 8 of Additional GI surgical procedure
.... 14.608 Outcome Measure List for QUARTET USA Trial
.... 14.609 Outcome Measure Report for QUARTET USA Trial
.... 14.610 Outcome Measure Report: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 14.611 Outcome Measures Report for NCT03640312
.... 14.612 Outcome Variables List for PARACHUTE Trial
.... 14.613 Outcome: Death or Major Traumatic Injury 30 days after Impact
.... 14.614 Outcome: Death or Major Traumatic Injury on Impact
.... 14.615 Outcome: Injury Severity Score 30 days after Impact
.... 14.616 Outcome: Injury Severity Score on Impact
.... 14.617 OutcomeDefinition: Injury Severity Score on Impact
.... 14.618 OutcomeDefinition: All-cause mortality
.... 14.619 OutcomeDefinition: American Diabetes Association composite triple end point for metabolic control
.... 14.620 OutcomeDefinition: Body weight
.... 14.621 OutcomeDefinition: Cardiovascular mortality
.... 14.622 OutcomeDefinition: Diabetes in remission
.... 14.623 OutcomeDefinition: Diabetic ketoacidosis
.... 14.624 OutcomeDefinition: End-stage kidney disease
.... 14.625 OutcomeDefinition: Genital infection
.... 14.626 OutcomeDefinition: HbA1c at 12 months
.... 14.627 OutcomeDefinition: HbA1c at 24 months
.... 14.628 OutcomeDefinition: HbA1c at 36 months
.... 14.629 OutcomeDefinition: HbA1c at 6 months
.... 14.630 OutcomeDefinition: HbA1c at 60 months
.... 14.631 OutcomeDefinition: Health-related quality of life
.... 14.632 OutcomeDefinition: Heart failure
.... 14.633 OutcomeDefinition: Mortality at 14 days
.... 14.634 OutcomeDefinition: New onset depression
.... 14.635 OutcomeDefinition: Nonfatal myocardial infarction
.... 14.636 OutcomeDefinition: Nonfatal myocardial infarction or stroke
.... 14.637 OutcomeDefinition: Nonfatal stroke
.... 14.638 OutcomeDefinition: Serious hyperglycaemia
.... 14.639 OutcomeDefinition: Severe gastrointestinal events
.... 14.640 OutcomeList: Clinical Outcomes for Effects of Bariatric Surgery
.... 14.641 OutcomeMeasureReport: GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.642 OutcomeVariable: American Diabetes Association composite triple end point for metabolic control at 5 years
.... 14.643 OutcomeVariable: HbA1c at 12 months
.... 14.644 OutcomeVariable: HbA1c at 24 months
.... 14.645 OutcomeVariable: HbA1c at 36 months
.... 14.646 OutcomeVariable: HbA1c at 6 months
.... 14.647 OutcomeVariable: HbA1c at 60 months
.... 14.648 OutcomeVariable: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups at end of follow-up
.... 14.649 OutcomeVariable: New onset depression
.... 14.650 OutcomeVariable: Nonfatal myocardial infarction or stroke
.... 14.651 OutcomeVariable: Remission of diabetes
.... 14.652 OutcomeVariablesList: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 14.653 OutcomeVariable_Additional_GI_surgical_procedure
.... 14.654 OutcomeVariable_All_cause_mortality
.... 14.655 OutcomeVariable_Treatment_with_opioids
.... 14.656 PARACHUTE Trial baseline characteristics
.... 14.657 PARACHUTE Trial non participants
.... 14.658 PARACHUTE trial participant flow report
.... 14.659 PARACHUTE Trial Participants
.... 14.660 PARACHUTE Trial Participants assigned an empty backpack
.... 14.661 PARACHUTE trial participants assigned parachute
.... 14.662 PARACHUTE Trial Participants available for randomization
.... 14.663 PARACHUTE Trial Participants deemed unsuitable by investigator
.... 14.664 PARACHUTE Trial Participants randomized into groups
.... 14.665 PARACHUTE Trial Participants randomized into groups for screened group
.... 14.666 PARACHUTE Trial Participants randomized into groups with comparator
.... 14.667 PARACHUTE Trial Participants randomized into groups with intervention
.... 14.668 PARACHUTE Trial Participants that completed 30 day follow up
.... 14.669 PARACHUTE Trial Participants that completed 30 day follow up with comparator
.... 14.670 PARACHUTE Trial Participants that completed 30 day follow up with intervention
.... 14.671 PARACHUTE Trial Participants that completed jump and 5 minute follow-up
.... 14.672 PARACHUTE Trial Participants that completed jump and 5 minute follow-up with comparator
.... 14.673 PARACHUTE Trial Participants that completed jump and 5 minute follow-up with intervention
.... 14.674 PARACHUTE Trial Participants that declined randomization
.... 14.675 PARACHUTE Trial Participants with no contact at 30 days
.... 14.676 PARACHUTE Trial Participants with no contact at 30 days with comparator
.... 14.677 PARACHUTE Trial Participants with no contact at 30 days with intervention
.... 14.678 PARACHUTE Trial Results
.... 14.679 Parachute use to prevent death and major trauma when jumping from aircraft: randomized controlled trial.
.... 14.680 Parachute vs Empty Backpack in PARACHUTE Trial
.... 14.681 Participant Flow Report for NCT03640312
.... 14.682 Participant Flow Report for QUARTET USA Trial
.... 14.683 Participant Flow Variables List for PARACHUTE Trial
.... 14.684 ParticipantFlow: 2018 Norwegian Cohort Included in Analysis
.... 14.685 ParticipantFlow: 2018 Norwegian Cohort Medical Group Included in Analysis
.... 14.686 ParticipantFlow: 2018 Norwegian Cohort Surgical Group Included in Analysis
.... 14.687 ParticipantFlowEvidence: 2018 Norwegian Cohort Excluded from Analysis
.... 14.688 ParticipantFlowMeasure: Dropout due to stopping intervention
.... 14.689 ParticipantFlowMeasure: Exclusion from analysis
.... 14.690 ParticipantFlowMeasure: Inclusion in analysis
.... 14.691 Participants Excluded from PARACHUTE Study
.... 14.692 Participants_in_Anticoagulation_for_COVID_19_Combined_ATTACC_ACTIV_4a_and_REMAP_CAP_RCT_hospitalized_not_critically_ill
.... 14.693 Patients_who_are_hospitalized_for_COVID_19_and_who_are_not_critically_ill
.... 14.694 Percentage of Participants With Potentially Related Adverse Events (NCT03640312)
.... 14.695 Percentage of Participants With Potentially Related Adverse Events at 12 weeks for Candesartan in NCT03640312
.... 14.696 Percentage of Participants With Potentially Related Adverse Events at 12 weeks for QUARTET LDQT in NCT03640312
.... 14.697 Percentage of Participants With Potentially Related Adverse Events at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.698 Percentage of Participants With Serious Adverse Events (SAEs) (NCT03640312)
.... 14.699 Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks for Candesartan in NCT03640312
.... 14.700 Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks for QUARTET LDQT in NCT03640312
.... 14.701 Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.702 Placebo
.... 14.703 PlanDefinition for Recommendation: ADA Obesity Management Recommendation 8.16
.... 14.704 PlanDefinition for Recommendation: ADA Obesity Management Recommendation 8.17
.... 14.705 PreprintCitation: Nigella Sativa for COVID-19 OSF Preprint
.... 14.706 Proportion of Patients With Adverse Event Free Hypertension Control (NCT03640312)
.... 14.707 Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks for Candesartan in NCT03640312
.... 14.708 Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks for QUARTET LDQT in NCT03640312
.... 14.709 Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.710 Proportion of Patients With Hypertension Control (NCT03640312)
.... 14.711 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 12 weeks at (NCT03640312)
.... 14.712 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 12 weeks for Candesartan in NCT03640312
.... 14.713 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 12 weeks for QUARTET LDQT in NCT03640312
.... 14.714 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 6 weeks at (NCT03640312)
.... 14.715 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 6 weeks for Candesartan in NCT03640312
.... 14.716 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 6 weeks for QUARTET LDQT in NCT03640312
.... 14.717 Proportion of Patients With Hypertension Control at 6 and 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.718 Quadpill once daily
.... 14.719 QUARTET USA Trial Control Group
.... 14.720 QUARTET USA Trial Quadpill group
.... 14.721 randomized into groups for PARACHUTE Trial
.... 14.722 Rate of Adverse Events of Special Interest (NCT03640312)
.... 14.723 Rate of Adverse Events of Special Interest at 12 weeks for Candesartan in NCT03640312
.... 14.724 Rate of Adverse Events of Special Interest at 12 weeks for QUARTET LDQT in NCT03640312
.... 14.725 Rate of Adverse Events of Special Interest at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.726 Rate of Death or Major Traumatic Injury on Impact with comparator
.... 14.727 Rate of Death or Major Traumatic Injury on Impact with intervention
.... 14.728 Reasons for exclusion from QUARTET USA Trial
.... 14.729 Recommendation Eligibility Criteria for Bariatric Surgery (ADA Recommendation 8.17)
.... 14.730 Recommendation Justification Code System
.... 14.731 Recommendation Rating: ADA Obesity Management Recommendation 8.16
.... 14.732 Recommendation: ADA Obesity Management Recommendation 8.16
.... 14.733 Recommendation: ADA Obesity Management Recommendation 8.16-adapted
.... 14.734 Recommendation: ADA Obesity Management Recommendation 8.17
.... 14.735 RecommendationEligibilityCriteria: Eligibility Criteria for Bariatric Surgery (ADA Recommendation 8.16)
.... 14.736 Remdesivir
.... 14.737 Remdesivir IV 200 mg once then 100 mg once daily for 9 days
.... 14.738 Results Section for NCT03640312
.... 14.739 Risk of Bias Assessment of Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill patients with COVID-19
.... 14.740 Risk of Bias Assessment of PARACHUTE trial
.... 14.741 Risk Of Bias Type Value Set
.... 14.742 Screened Group PARACHUTE Trial
.... 14.743 Search Strategy for NMA_Diabetes
.... 14.744 SearchResults: PubMed search for Wonder Woman
.... 14.745 SearchStrategy: PubMed and Embase search for van Veldhuisen 2022 systematic review
.... 14.746 SearchStrategy: PubMed search for Wonder Woman
.... 14.747 Sex
.... 14.748 Sex with comparator
.... 14.749 Sex with intervention
.... 14.750 SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.751 SoaPlanDefinition: Follow-up assessment 3 months after study start
.... 14.752 SoftwareCitation: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter
.... 14.753 Spanish or English Value Set
.... 14.754 Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 14.755 StudyCitation: 2022 Systematic Review of bariatric surgery mortality effect 35243488
.... 14.756 StudyEligibilityCriteria: Eligibility Criteria for DIBASY Trial
.... 14.757 StudyEligibilityCriteria: Obese patients ≥ 18 years old
.... 14.758 StudyEligibilityCriteria: Type 2 diabetes and elevated BMI in 2016 meta-analysis
.... 14.759 StudyEligibilityCriteria_Eligibility_Criteria_for_Bariatric_Surgery_Randomized_Trial_Diabetes_Surgery_Study
.... 14.760 StudyGroup: Diabetes Surgery Study Trial Enrollment Group
.... 14.761 StudyGroup: Severely Obese Adults 2018 Norwegian Cohort
.... 14.762 StudyGroup_DIBASY_Trial_Enrollment_Group
.... 14.763 SummaryOfFindings: Bariatric Surgery Summary of Findings Example for GIN 2022
.... 14.764 SummaryOfFindings: GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.765 SummaryOfFindings: SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.766 SummaryOfNetEffect: Bariatric Surgery Summary of Net Effect Contributions Example for GIN 2022
.... 14.767 SystematicReviewEligibilityCriteria: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer
.... 14.768 SystematicReviewExcludedStudies: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer
.... 14.769 SystematicReviewIncludedStudies: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer
.... 14.770 Systolic blood pressure at 12 weeks
.... 14.771 Time to integration of results in a recommendation
.... 14.772 VariableDefinition: Comparator
.... 14.773 VariableDefinition: Condition(s)
.... 14.774 VariableDefinition: Date of birth
.... 14.775 VariableDefinition: Date of measurement
.... 14.776 VariableDefinition: Gender
.... 14.777 VariableDefinition: NTproBNP
.... 14.778 VariableDefinition: Unit
.... 14.779 Velocity
.... 14.780 Velocity comparing intervention vs. comparator
.... 14.781 Velocity for enrolled group
.... 14.782 Velocity for non participant group
.... 14.783 Velocity with comparator
.... 14.784 Velocity with intervention
.... 14.785 WebPageCitation: A HEvKA Update Summary
.... 14.786 Weight
.... 14.787 Weight with comparator
.... 14.788 Weight with intervention